Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
暂无分享,去创建一个
D. Ankerst | V. Heinemann | R. Laubender | S. Stintzing | A. Schalhorn | D. Modest | C. Giessen | C. Schulz | L. V. von Weikersthal | N. Moosmann